First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Real-World Outcomes of First-Line CDK4/6 Inhibitor Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer: Insights from Ho Chi Minh City Oncology Hospital, Vietnam

  • By

  • Thi Hong Duc Phan

  • Hoang Quy Nguyen

  • September 7, 2026

Share

Original Source(s)

Related Content